ITMCTR2100004681招募中1 期
Effects of Jia Wei Dachaihu Tang on gut microbiota and inflammatory markers in patients with overweight or obesity: a randomized, controlled, double-blinded trial
Hospital of Chengdu University of Traditional Chinese Medicine0 个研究点开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional study
入排标准
- 性别
- All
入选标准
- •1. Over 18 years to under 65 years of age;
- •2. Body mass index with >= 25.0 kg/m2(overweight/ obese);
- •3. Able and willing to provide informed consent and comply with study procedures.
排除标准
- •1.Patients with the endocrine disease that may affect body weight, such as hypothyroidism, Cushing's syndrome, or those with thyroid-stimulating hormone concentration < 0.1 uIU/ml or > 10.0 uIU/ml.
- •2.Subjects who are already on a diet or undertaking heavy exercise for weight control purposes.
- •3.Subjects who have undergone surgical procedures for weight control.
- •4.Patients with a history of neurological or psychological disease or currently suffering from such diseases (schizophrenia, epilepsy, alcoholism, drug addiction, anorexia, bulimia, etc.)
- •5.Patients with a history or existence of eating disorders such as anorexia nervosa or bulimia nervosa, etc.
- •6.Patients with experience of medications that could have an effect on weight within last 3 months such as appetite suppressant, laxative, or oral steroid, thyroid hormone, amphetamine, cyproheptadine, phenothiazine, or medications affecting absorption, metabolism, and excretion.
- •7.Subjects who diagnosed with diabetes or other metabolic health disturbances.
- •8.Patients who have used other clinical trial drugs within 3 months.
- •9.Subjects who have had weight changes > 10% of their previous weight within the last 6 months.
- •10.Those whose aspartate transaminase or alanine transaminase exceeds five times the normal upper limit (200 IU/L).
- •11.Kidney dialysis patients or those with creatinine concentration more than twice the normal upper limit.
- •12.Those who are in seriously unstable medical condition, such as cardiovascular disease, respiratory disease, gastrointestinal disease, hepatobiliary disease, metabolic disease, endocrine disease, renal disease, or problems in the urinary reproductive system and nervous system.
- •13.Those who have had a diagnosis or have been treated for malignant tumors within the last 5 years.
- •14.Women who are pregnant, planning to become pregnant, or lactating, or subjects who do not agree to use effective methods of contraception during the clinical trial (Oral contraceptives are not allowed during the clinical trial.).
- •15.Receiving medications or supplements that could affect gut microbiota during the last 3 months(examples: antibiotics, probiotics, prebiotics, laxatives, etc.).
研究者
相似试验
招募中
1 期
Effect of Jianpi Qinghua Decoction on gut microbiota, intestinal permeability and glycolipid metabolism in newly diagnosed T2DM patients: study protocol for a randomized, double-blind, placebo-controlled clinical trialFirst-onset type 2 diabetesITMCTR2100004341Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
尚未招募
2 期
Effect of Gudadyavaleha on Gut Microbiome and Clinical Profile in Tamak Swas w.s.r. Childhood Bronchial AsthmaCTRI/2024/03/063402ational Institute of Ayurveda, Jaipur
招募中
不适用
The Effect of Zhichan Granule on intestinal flora metabolism in patients with Parkinson's diseaseParkinson's diseaseITMCTR2000004015Shanghai Hospital of Traditional Chinese Medicine
已完成
1 期
Assessment of the influence of the gut microbiome on tacrolimus pharmacokinetics in healthy volunteersPharmacokinetic trial in healthy volunteersDRKS00032072niversitätsklinikum Heidelberg, Im Wege der Auftragsverwaltung für die Universität Heidelberg, Medizinische Fakultät Heidelberg20
进行中（未招募）
不适用
How do polyphenols, carotenoids and glucosinolates in our diets affect the diversity of our gut microbiome?utrition effects on gut microbiomeNutritional, Metabolic, EndocrineISRCTN14510401Quadram Institute27